Perry Cassandra H, Smith William R, St Claire Robert L, Brouwer Kenneth R
Qualyst, Inc., Durham, NC 27713, USA.
J Biomol Screen. 2011 Apr;16(4):427-35. doi: 10.1177/1087057111400192. Epub 2011 Mar 10.
Predictions of the absorption, distribution, metabolism, excretion, and toxicity of compounds in pharmaceutical development are essential aspects of the drug discovery process. B-CLEAR is an in vitro system that uses sandwich-cultured hepatocytes to evaluate and predict in vivo hepatobiliary disposition (hepatic uptake, biliary excretion, and biliary clearance), transporter-based hepatic drug-drug interactions, and potential drug-induced hepatotoxicity. Automation of predictive technologies is an advantageous and preferred format in drug discovery. In this study, manual and automated studies are investigated and equivalence is demonstrated. In addition, automated applications using model probe substrates and inhibitors to assess the cholestatic potential of drugs and evaluate hepatic drug transport are examined. The successful automation of this technology provides a more reproducible and less labor-intensive approach, reducing potential operator error in complex studies and facilitating technology transfer.
在药物研发过程中,预测化合物的吸收、分布、代谢、排泄和毒性是药物发现过程的重要方面。B-CLEAR是一种体外系统,它使用三明治培养的肝细胞来评估和预测体内肝胆处置(肝脏摄取、胆汁排泄和胆汁清除率)、基于转运体的肝药相互作用以及潜在的药物性肝毒性。预测技术的自动化是药物发现中一种有利且首选的形式。在本研究中,对人工和自动化研究进行了调查并证明了等效性。此外,还研究了使用模型探针底物和抑制剂来评估药物的胆汁淤积潜力并评估肝脏药物转运的自动化应用。这项技术的成功自动化提供了一种更可重复且劳动强度更低的方法,减少了复杂研究中潜在的操作员误差并促进了技术转移。